BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38760435)

  • 1. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals.
    Zhang P; Zeng Y; Yang S; Ye C; Wang M; Peng T; Li L; Dong X
    Sci Rep; 2024 May; 14(1):11320. PubMed ID: 38760435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease.
    Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim D; Kim YJ; Yoon JH; Han K; Cho EJ
    BMC Med; 2023 Jan; 21(1):4. PubMed ID: 36600263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
    Lee H; Lim TS; Kim SU; Kim HC
    Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
    Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
    Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study.
    Park MK; Hur MH; Moon HS; Shin H; Chung SW; Won S; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Liver Int; 2024 Mar; 44(3):799-810. PubMed ID: 38230848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
    Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
    Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.
    Guo Y; Yang J; Ma R; Zhang X; Guo H; He J; Wang X; Cao B; Maimaitijiang R; Li Y; Peng X; Zhang S; Guo S
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
    Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
    Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
    Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
    Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.
    Cen C; Fan Z; Ding X; Tu X; Liu Y
    Sci Rep; 2024 Jun; 14(1):12645. PubMed ID: 38825630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.
    Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B
    Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
    Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
    Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
    Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.
    Xie ZQ; Li HX; Wang BK; Yang ZM; Zhang ZY; Tan WL; Li WX; Wang QB; Yang L; Zhuang HK; Tang CW; Shang CZ; Chen YJ
    Eur J Intern Med; 2023 Apr; 110():62-70. PubMed ID: 36754655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
    Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
    Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.